BrainsWay is demonstrating a compelling inflection point, with revenue growth accelerating to 37.8% in 2026Q2 and operating margins expanding to 14.0%, driven by strong gross margins of ~75% and emerging operating leverage. The company's balance sheet is excep...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | $0.14+40.0% vs $0.10 | $17M+3.4% vs $17M |
Q2 2026 May 13, 2026 | $0.12+140.0% vs $0.05 | $16M+6.1% vs $15M |
Q2 2026 Mar 11, 2026 | $0.14+133.3% vs $0.06 | $15M+3.8% vs $14M |
Q4 2025 Nov 11, 2025 | $0.04-20.0% vs $0.05 | $14M+3.7% vs $13M |
Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity
Brainsway (NASDAQ: BWAY - Get Free Report) and Green Thumb Industries (OTCMKTS:GTBIF - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Profitability This table compares Brainsway and Green
The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Benchmark BWAY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BrainsWay Ltd. (BWAY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.45 | $527.55M | 37.36 | 27.33% | 14.62% | 11.26% | — | |
| $2.88 | $200.41M | -4.88 | 99.17% | -19.62% | -126.4% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $77.16 | $4.24B | -17.34 | 10.74% | 12.82% | 15.41% | — | |
| $153.49 | $9.05B | -46.80 | 32.33% | -30.68% | -27.07% | — | |
| $27.57 | $228.28M | 32.06 | 16.97% | 15.32% | 23.38% | — |
BrainsWay Ltd. (BWAY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BWAY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BrainsWay Ltd. (BWAY) stock FAQ — growth, dividends, profitability & financials explained
BrainsWay Ltd. (BWAY) reported $61.0M in revenue for fiscal year 2025. This represents a 16644% increase from $0.4M in 2012.
BrainsWay Ltd. (BWAY) grew revenue by 27.3% over the past year. This is strong growth.
Yes, BrainsWay Ltd. (BWAY) is profitable, generating $9.5M in net income for fiscal year 2025 (14.6% net margin).
BrainsWay Ltd. (BWAY) has a return on equity (ROE) of 11.3%. This is reasonable for most industries.
BrainsWay Ltd. (BWAY) generated $5.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
